Isradipine: a profile in essential hypertension

Isradipine is a new dihydropyridine-derived calcium antagonist. It possesses marked vascular selectivity, resulting in a powerful vasodilating action, whereas, in practical terms, it is devoid of cardiac effects. The usefulness of isradipine in the treatment of arterial hypertension is well documented, both when used as single-drug treatment and in combination with other agents, particularly, beta-blockers. Isradipine is well tolerated and does not negatively affect quality of life or capacity for physical exercise. It does not cause metabolic disturbances and, apart from the typical dihydropyridine-type vascular side-effects, specifically, flushing and ankle oedema, there are no specific adverse effects. Even ankle oedema is apparently relatively rare with this compound. Studies in animal models show that isradipine has a potent anti-atherosclerotic effect, and a brain tissue-preserving effect after experimental stroke, in doses that are relevant for antihypertensive treatment. If such results can be confirmed in humans, they will undoubtedly be of great clinical importance.